Laura P B Elbers1, Carla Moran2, Victor Ea Gerdes3, Bregje van Zaane4, Joost Meijers5, Erik Endert6, Greta Lyons7, V Krishna Chatterjee8, Peter H Bisschop9, Eric Fliers10. 1. L Elbers, Internal Medicine, Medical Center Slotervaart, Amsterdam, Netherlands l.p.elbers@amc.uva.nl. 2. C Moran, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom of Great Britain and Northern Ireland. 3. V Gerdes, Internal Medicine, Medical Center Slotervaart, Amsterdam, Netherlands. 4. B van Zaane, Internal Medicine, Medical Center Slotervaart, Amsterdam, Netherlands. 5. J Meijers, Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 6. E Endert, Laboratory of Endocrinology and Radiochemistry, Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 7. G Lyons, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom of Great Britain and Northern Ireland. 8. V Chatterjee, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom of Great Britain and Northern Ireland. 9. P Bisschop, Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 10. E Fliers, Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Abstract
OBJECTIVE: Hyperthyroidism is associated with a hypercoagulable state, but the underlying mechanism is unknown. Patients with resistance to thyroid hormone (RTH) due to defective thyroid hormone receptor β (TRβ) exhibit elevated circulating thyroid hormones (TH) with refractoriness to TH action in TRβ-expressing tissues. We tested the hypothesis that the hypercoagulable state in hyperthyroidism is mediated via the TRβ. DESIGN: We conducted a cross-sectional study from November 2013 to January 2015 in 3 hospitals in the Netherlands and the United Kingdom. METHODS: Patients with RTH due to defective TRβ (n=18), patients with hyperthyroidism (n=16) and euthyroid subjects (n=18) were included. TH concentrations and markers of coagulation and fibrinolysis were measured. Data are expressed as median [interquartile range]. RESULTS: Free thyroxine (FT4) levels were slightly higher in hyperthyroid patients than in RTH patients (53.9 [30.5-70.0] and 34.9 [28.4-42.2]pmol/l, respectively, P=0.042). Both groups had raised FT4 levels compared to euthyroid subjects (14.0 [13.0-15.8] pmol/l, P≤0.001). Levels of von Willebrand factor (VWF), factor (F) VIII, fibrinogen, and D-dimer were significantly higher in hyperthyroid patients than in RTH patients (VWF 231 [195-296] vs. 111 [82-140]%, FVIII 215 [192-228] vs. 145 [97-158]%, fibrinogen 3.6 [3.0-4.4] vs. 2.8 [2.5-3.2]g/L, D-dimer 0.41 [0.31-0.88] vs. 0.20 [0.17-0.26]mg/L, respectively, P≤0.001), while there were no differences between RTH patients and euthyroid controls. CONCLUSIONS: Parameters of coagulation and fibrinolysis were elevated in hyperthyroid patients compared to patients with RTH due to defective TRβ, whereas these parameters were not different between euthyroid controls and RTH patients, despite elevated FT4 concentrations in RTH patients. This indicates that the procoagulant effects observed in hyperthyroidism are mediated via the TRβ.
OBJECTIVE: Hyperthyroidism is associated with a hypercoagulable state, but the underlying mechanism is unknown. Patients with resistance to thyroid hormone (RTH) due to defective thyroid hormone receptor β (TRβ) exhibit elevated circulating thyroid hormones (TH) with refractoriness to TH action in TRβ-expressing tissues. We tested the hypothesis that the hypercoagulable state in hyperthyroidism is mediated via the TRβ. DESIGN: We conducted a cross-sectional study from November 2013 to January 2015 in 3 hospitals in the Netherlands and the United Kingdom. METHODS: Patients with RTH due to defective TRβ (n=18), patients with hyperthyroidism (n=16) and euthyroid subjects (n=18) were included. TH concentrations and markers of coagulation and fibrinolysis were measured. Data are expressed as median [interquartile range]. RESULTS: Free thyroxine (FT4) levels were slightly higher in hyperthyroid patients than in RTH patients (53.9 [30.5-70.0] and 34.9 [28.4-42.2]pmol/l, respectively, P=0.042). Both groups had raised FT4 levels compared to euthyroid subjects (14.0 [13.0-15.8] pmol/l, P≤0.001). Levels of von Willebrand factor (VWF), factor (F) VIII, fibrinogen, and D-dimer were significantly higher in hyperthyroid patients than in RTH patients (VWF 231 [195-296] vs. 111 [82-140]%, FVIII 215 [192-228] vs. 145 [97-158]%, fibrinogen 3.6 [3.0-4.4] vs. 2.8 [2.5-3.2]g/L, D-dimer 0.41 [0.31-0.88] vs. 0.20 [0.17-0.26]mg/L, respectively, P≤0.001), while there were no differences between RTH patients and euthyroid controls. CONCLUSIONS: Parameters of coagulation and fibrinolysis were elevated in hyperthyroid patients compared to patients with RTH due to defective TRβ, whereas these parameters were not different between euthyroid controls and RTH patients, despite elevated FT4 concentrations in RTH patients. This indicates that the procoagulant effects observed in hyperthyroidism are mediated via the TRβ.
Authors: M J Diekman; B Zandieh Doulabi; M Platvoet-Ter Schiphorst; E Fliers; O Bakker; W M Wiersinga Journal: J Endocrinol Date: 2001-03 Impact factor: 4.286
Authors: Ruud S Kootte; Danka J F Stuijver; Olaf M Dekkers; Bregje van Zaane; Eric Fliers; Suzanne C Cannegieter; Victor E A Gerdes Journal: Thromb Haemost Date: 2012-01-11 Impact factor: 5.249
Authors: Barbara Sjouke; Gisle Langslet; Richard Ceska; Stephen J Nicholls; Steven E Nissen; Maria Öhlander; Paul W Ladenson; Anders G Olsson; G Kees Hovingh; John J P Kastelein Journal: Lancet Diabetes Endocrinol Date: 2014-02-18 Impact factor: 32.069
Authors: Elena Bochukova; Nadia Schoenmakers; Maura Agostini; Erik Schoenmakers; Odelia Rajanayagam; Julia M Keogh; Elana Henning; Jana Reinemund; Evelien Gevers; Margarita Sarri; Kate Downes; Amaka Offiah; Assunta Albanese; David Halsall; John W R Schwabe; Murray Bain; Keith Lindley; Francesco Muntoni; Faraneh Vargha-Khadem; Faraneh Vargha Khadem; Mehul Dattani; I Sadaf Farooqi; Mark Gurnell; Krishna Chatterjee Journal: N Engl J Med Date: 2011-12-14 Impact factor: 91.245
Authors: Christina Ellervik; Samia Mora; Aleksander Kuś; Bjørn Åsvold; Eirini Marouli; Panos Deloukas; Rosalie B T M Sterenborg; Alexander Teumer; Stephen Burgess; Maria Sabater-Lleal; Jennifer Huffman; Andrew D Johnson; David-Alexandre Trégouet; Nicolas L Smith; Marco Medici; Paul S DeVries; Daniel I Chasman; Alisa D Kjaergaard Journal: Thyroid Date: 2021-08-05 Impact factor: 6.506
Authors: Maik Pietzner; Beatrice Engelmann; Tim Kacprowski; Janine Golchert; Anna-Luise Dirk; Elke Hammer; K Alexander Iwen; Matthias Nauck; Henri Wallaschofski; Dagmar Führer; Thomas F Münte; Nele Friedrich; Uwe Völker; Georg Homuth; Georg Brabant Journal: BMC Med Date: 2017-01-09 Impact factor: 8.775
Authors: Ahmed Elkhalifa Elawad Elhassan; Mohammed Omer Khalil Ali; Amina Bougaila; Mohammed Abdelhady; Hassan Abuzaid Journal: J Investig Med High Impact Case Rep Date: 2020 Jan-Dec